Using probenecid to treat heart failure in veterans
Official title: Treatment of Veterans with Heart Failure with Reduced Ejection Fraction with Probenecid
Funded at Cincinnati VA Medical Center Research · NIH-11044133 · Data updated 2026-11-12
This study is looking at whether a safe medication called probenecid can help improve heart function in veterans with heart failure, making their hearts work better and feel stronger.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati VA Medical Center Research NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | January 1, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| NIH project number | 5I01CX001968-05 |
| Project ID | NIH-11044133 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are veterans aged 21 and older who have been diagnosed with heart failure with reduced ejection fraction.
✕Less likely to help
Patients who do not have heart failure or those with other types of heart conditions may not benefit from this research.
What this research studies
This research investigates the use of probenecid, a safe and commonly used medication, to improve heart function in veterans suffering from heart failure with reduced ejection fraction (HFrEF). The study focuses on how probenecid acts on specific receptors in heart cells to enhance calcium handling and contractility, potentially leading to better heart performance. By building on previous laboratory findings and a small pilot study, this research aims to provide a new treatment option for veterans with this serious condition.
Why it matters
Potential benefit: If successful, this research could offer a novel and effective treatment for veterans with heart failure, improving their quality of life and survival rates.
How similar studies have gone: Previous studies have shown promising results with similar approaches, particularly in small pilot studies, indicating potential for further exploration.
Where this research is happening
-
Cincinnati VA Medical Center Research
Cincinnati, United States Active
Researchers
- Principal investigator: Rubinstein, Jack — Cincinnati VA Medical Center Research
- Study coordinator: Rubinstein, Jack
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.